MAPT and Alzheimer disease: These factors can account for this one discrepancy.Similarly, other studies have shown a marked loss of thickness after the age of 60[42] as well as preservation of entorhinal cortex and other nearby structures [44] but without CSF exclusionary criteria, Recent studies have showed that using both CSF Aβ42 and tau biomarkers is more precise in excluding AD [45], and that CSF tau in particular is associated with entorhinal cortex atrophy in incipient disease [46].